StemCell Therapy

New York, July 1 : A team of US scientists, led by an Indian-origin researcher revealed that SARS-CoV-2 (coronavirus), the virus behind Covid-19, can infect heart cells in a lab dish.

This suggests it may be possible for heart cells in Covid-19 patients to be directly infected by the virus.

The discovery, published today in the journal Cell Reports Medicine, was made using heart muscle cells that were produced by stem cell technology.

We not only uncovered that these stem cell-derived heart cells are susceptible to infection by a novel coronavirus, but that the virus can also quickly divide within the heart muscle cells, said study researcher Arun Sharma from the Cedars-Sinai Board of Governors Regenerative Medicine Institute in the US.

Even more significant, the infected heart cells showed changes in their ability to beat after 72 hours of infection, Sharma added.Although many COVID-19 patients experience heart problems, the reasons remain unclear. Pre-existing cardiac conditions or inflammation and oxygen deprivation resulting from the infection have all been implicated.

But there has until now been only limited evidence the SARS-CoV-2 virus directly infects the individual muscle cells of the heart.The study also demonstrated human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile.This offers further confirmation the cells can be actively infected by the virus and activate innate cellular defence mechanisms in an effort to help clear-out the virus.

This viral pandemic is predominately defined by respiratory symptoms, but there are also cardiac complications, including arrhythmia, heart failure and viral myocarditis, said study co-author Clive Svendsen.

While this could be the result of massive inflammation in response to the virus, our data suggest that the heart could also be directly affected by the virus in Covid-19, Svendsen added.

Researchers also found that treatment with an ACE2 antibody was able to blunt viral replication on stem cell-derived heart cells, suggesting that the ACE2 receptor could be used by SARS-CoV-2 to enter human heart muscle cells.

By blocking the ACE2 protein with an antibody, the virus is not as easily able to bind to the ACE2 protein, and thus cannot easily enter the cell, said Sharma. This not only helps us understand the mechanisms of how this virus functions, but also suggests therapeutic approaches that could be used as a potential treatment for SARS-CoV-2 infection, he explained.

The study used human induced pluripotent stem cells (iPSCs), a type of stem cell that is created in the lab from a persons blood or skin cells. IPSCs can make any cell type found in the body, each one carrying the DNA of the individual. This work illustrates the power of being able to study human tissue in a dish, the authors wrote.

More here:
Rahul Gandhi to interact with nurses on July 1 - WeForNews

Organoids are paving the way to understanding the effects of Covid-19 on the human body

These are lab-grown mini-organs like kidneys, lungs, livers and brains

This method is considered more ethical than testing on animals, but has its limitations

And no, this isnt like the human cloning you see in movies like The Island.

They are grown from human embryonic stem cells, programmed to organise themselves into whichever organ the scientist needs to experiment with.

They resemble tiny grey blobs, but are an important tool in replicating the pathology of viruses like Covid-19 in order to understand and discover treatments to help fight them.

Three methods of investigation

Various coronavirus studies have been done on lung, kidney, liver and cardiovascular system organoids.

According to a review published in Cell Press, the use of organoids is one of three methods of investigating the effects of a disease on the human body in a lab. The others are using human airway epithelial cells and animal testing.

See how they grow brain organoids below:

Some of the research so far has found invaluable data on Covid-19. Research published in Science on small intestinal organoids found that not only was it a target for the virus, it also was a hot spot for its replication.

Another study from China published in bioRxiv also analysed how receptive lung organoids are to the virus, and tested drugs like imatinib and mycophenolic acid to see if it inhibited the viruss effects. They concluded that organoids would be a powerful tool in faster screening of more treatments not yet ready for human trials.

While organoids better represent human cells, animal testing is sometimes considered more effective as it shows the effect of a virus and treatment across the whole biological system.

Organoids only show how a single organ is affected, and the human body is a system with many parts interacting with each other and not in isolation.

Animals used in Covid-19 studies include transgenic mice, Syrian hamsters, cats, ferrets and macaques. The virus, however, does not seem to replicate itself in ducks, pigs and chickens.

By-product of immune response

Experts, however, told Nature that organoids are much cheaper, produce faster results, and have far fewer ethical complications than testing on animals.

But they also note that its too early to tell if the findings from organoid studies are yet relevant enough, as theres a need for more complex organoids for better results.

It would also be difficult to ascertain whether Covid-19 is causing the damage in these organs, or if the damage is a byproduct of the bodys immune response, like the deadly cytokine storm.

Image credit: Pixabay

Read more:
Lab-grown mini-organs reveal the damage inflicted by Covid-19 - Health24

The frenetic search for the miracle that will rid the world of COVID-19 is branching out in a thousand directions, and a large part of the microbial treasure hunt is going on in the Bay Area, where major progress has been made in the 100 days since residents were ordered to shelter in place.

Scientists at universities, laboratories, biotechnology companies and drug manufacturers are combing through blood plasma taken from infected patients for secrets that will help them fight the disease.

The key is likely a super-strength antibody found in some patients. But researchers must first figure out how those antibodies work and how they can be harnessed and used to stop the many health problems associated with COVID-19, particularly acute respiratory distress syndrome, or ARDS, which has killed more people than any other complication connected to the disease.

Other developments showing promise include injections of mesenchymal stem cells, found in bone marrow and umbilical cords, that doctors are studying to battle inflammation caused by ARDS. And a steroid called dexamethasone reduced the number of deaths by halting the overreactive immune responses in seriously ill patients in the United Kingdom.

In all, more than 130 vaccines and 220 treatments are being tested worldwide.

What follows is a list of some of the most promising elixirs, medications and vaccines with ties to the Bay Area:

Monoclonal antibodies / Vir Biotechnology, San Francisco: Scientists at Vir and several institutions, including Stanford and UCSF, are studying monoclonal antibodies, which are clones of coronavirus-fighting antibodies produced by COVID-19 patients.

The idea is to utilize these neutralizing antibodies which bind to the virus crown-like spikes and prevent them from entering and hijacking human cells.

Only about 5% of coronavirus patients have these super-strength antibodies, and those people are believed to be immune to a second attack.

The trick for scientists at Vir is to identify these neutralizing antibodies, harvest, purify and clone them. If they succeed, the resulting monoclones could then be used to inoculate people and it is hoped give them long-term immunity against the coronavirus. The company recently signed a deal with Samsung Biologics, in South Korea, to scale up production of a temporary vaccine in the fall after clinical trials are complete.

Another monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn. The companys chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Interferon-lambda / Stanford University: Doctors at Stanford are running a trial to see if interferon-lambda, which is administered by injection, helps patients in the early stages of COVID-19. Interferon-lambda is a manufactured version of a naturally occurring protein that has been used to treat hepatitis. Stanford doctors hope it will boost the immune system response to coronavirus infections.

Dr. Upinder Singh, a Stanford infectious-disease expert, said the trial has enrolled more than 50 patients and is halfway finished. We have noted that patients tolerate the drug very well, she said.

Mesenchymal stem cells / UCSF and UC Davis Medical Center: UCSF Dr. Michael Matthay is leading a study about whether a kind of stem cell found in bone marrow can help patients with ARDS. Matthay hopes that the stem cells can help reduce the inflammation associated with some of ARDS most dire respiratory symptoms, and help patients lungs to recover.

Matthay is aiming to enroll 120 patients in San Francisco, the UC Davis Medical Center in Sacramento and hospitals in a handful of other states. He said the trial, which includes a small number ARDS patients who dont have COVID-19, should have results within a year. So far 17 patients are enrolled in the trial, most of them in San Francisco.

Remdesivir / Gilead Sciences (Foster City): Remdesivir, once conceived as a potential treatment for ebola, was the first drug to show some promise in treating COVID-19 patients. The drug interferes with the process through which the virus replicates itself. A large study led by the federal government generated excitement in late April when officials said hospitalized patients who received remdesivir intravenously recovered faster than those who received a placebo.

A later study looking at dosage showed some benefit for moderately ill COVID-19 patients who received remdesivir for five days, but improvement among those who got it for 10 days was not statistically significant. Gilead, a drug company, recently announced that it will soon launch another clinical trial to see how remdesivir works on 50 pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. More than 30 locations in the U.S. and Europe will be involved in the trial, the company said.

Coronavirus crisis: 100 days

Editors note: Its been 100 days since the Bay Area sheltered in place, protecting itself from the coronavirus pandemic. What have we learned in that time? And what does the future hold for the region and its fight against COVID-19? The Chronicle explores the past 100 days and looks to the future in this exclusive report.

Favipiravir / Fujifilm Toyama Chemical (Stanford University): This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a Stanford University trial that began this month. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

Stanford epidemiologists want to see if favipiravir, which has shown promising results in other trials, prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. The Stanford study, the only outpatient trial for this drug in the nation, is enrolling 120 people who have been diagnosed with COVID-19 within the past 72 hours. Half of them will get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Colchicine / UCSF (San Francisco and New York): The anti-inflammatory drug commonly used to treat gout flare-ups is being studied in the U.S. by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the bodys production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19. About 6,000 patients are receiving colchicine or a placebo during the clinical trial, dubbed Colcorona, which began in March and is expected to be completed in September.

Selinexor / Kaiser Permanente: Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing, as a potential COVID-19 treatment. The drug has both antiviral and anti-inflammatory properties, and its administered orally, according to Kaisers Dr. Jacek Skarbinski. The trial aims to enroll 250 patients with severe symptoms at Kaiser and other hospitals that are participating nationwide.

VXA-COV2-1 / Vaxart, South San Francisco: The biotechnology company Vaxart is testing this drug to see if it is as effective at controlling COVID-19 as trials have shown it to be against influenza. VXA-COV2-1, the only potential vaccine in pill form, uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

Its the only vaccine (candidate) that activates the first line of defense, which is the mucosa, said Andrei Floroiu, Vaxarts chief executive, noting that intravenous vaccines kill the virus after it is inside the body. Our vaccine may prevent you from getting infected at all.

The drug was effective against influenza and norovirus in trials and appears to work on laboratory animals, Floroiu said. He expects trials of VXA-COV2-1 on humans to begin later this summer.

VaxiPatch / Verndari (Napa and UC Davis Medical Center): Napa vaccine company Verndari makes a patented adhesive patch that can deliver a vaccine instead of a shot. Now, the company is trying to make a vaccine for COVID-19 that they can administer through that patch. At UC Davis Medical Center in Sacramento, Verndari researchers are developing a potential vaccine that relies on the coronavirus spike-shaped protein. When injected into a person, the substance would ideally train their body to recognize the virus and fight it off without becoming ill.

A spokeswoman told The Chronicle that the companys preclinical tests have shown early, positive data in developing an immune response. Verndari hopes to move into the next phase of testing in the coming weeks and start clinical trials in humans this year.

If the vaccine is proved effective and safe, patients could receive it through the mail, according to company CEO Dr. Daniel Henderson. The patch would leave a temporary mark on the skin that patients could photograph and send to their doctor as proof they have taken the vaccine, Henderson has said.

Peter Fimrite and J.D. Morris are San Francisco Chronicle staff writers. Email: pfimrite@sfchronicle.com, jd.morris@sfchronicle.com Twitter: @pfimrite, @thejdmorris

Link:
Efforts at coronavirus vaccines and treatments abound in the Bay Area - San Francisco Chronicle

DUBLIN--(BUSINESS WIRE)--The "Global Stem Cell Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

The global stem cell market is experiencing growth, owing to the increasing number of clinical trials around the world.

North America, especially the United States, dominated the number of trials undergoing stem cell therapies. However, Asia-Pacific is growing at the highest growth rate. Stem cells are majorly used in regenerative medicine, especially in the field of dermatology. However, oncology is expected to grow at the highest growth rate, due to a large number of pipeline products present for the treatment of tumors or cancers. With the increase in the number of regenerative medicine centers, the stem cell market is also expected to increase in the future.

Stem cell banking is gaining importance with the support of government initiatives. The number of stem cell banks is increasing in developing countries, which is aiding the growth of the market. Also, increasing awareness about stem cell storage among the people has positively affected the market. Currently, the market is not well established in many therapeutic areas and has shown nascent success in history. However, it holds great potential in both the diagnosis and therapeutic fields.

Oncology Disorders Segment Expected to Exhibit the Fastest Growth Rate Over the Forecast Period

Cancer has a major impact on the world. According to the World Health Organization (WHO) 2018 data on cancer, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Moreover, Cancer Research UK suggests that the population suffering from cancer is expected to increase in the future. As per the report, if recent trends in the incidence of major cancers and population growth are consistent, it is predicted there will be 27.5 million new cancer cases worldwide each year by 2040.

Stem cell transplants are procedures that restore blood-forming stem cells in people who have had theirs destroyed by the very high doses of chemotherapy or radiation therapy. Embryonic stem cells (ESC) are the major source of stem cells for therapeutic purposes, due to their higher totipotency and indefinite lifespan, as compared to adult stem cells with lower totipotency and restricted lifespan. These advantages along with the increasing incidence of cancer is expected to help the growth of stem cell market

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall stem cell market with the United States contributing to the largest share in the market. The United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. Additionally, Mexico is a developing nation with the benefit of being a neighbor to the United States. This allows many companies to penetrate in Mexico as well. This helps the growth in the region.

Competitive Landscape

The stem cell market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific (Qiagen NV), Sigma Aldrich (A Subsidiary of Merck KGaA), Becton, Dickinson and Company, and Stem Cell Technologies, is in turn, increasing the overall competitive rivalry in the market. The product advancements and improvement in stem cell technology by the major players are increasing the competitive rivalry.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increased Awareness about Umbilical Stem Cell

4.2.2 Rising R&D Initiatives to Develop Stem Cell Therapies and Increasing Approvals for Clinical Trials in Stem Cell Research

4.2.3 Growing Demand for Regenerative Treatment Option

4.3 Market Restraints

4.3.1 Expensive Procedures

4.3.2 Regulatory Complications

4.3.3 Ethical and Moral Framework

4.4 Industry Attractiveness- Porter's Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Product Type

5.1.1 Adult Stem Cell

5.1.2 Human Embryonic Cell

5.1.3 Pluripotent Stem Cell

5.1.4 Other Product Types

5.2 By Application

5.2.1 Neurological Disorders

5.2.2 Orthopedic Treatments

5.2.3 Oncology Disorders

5.2.4 Injuries and Wounds

5.2.5 Cardiovascular Disorders

5.2.6 Other Applications

5.3 By Treatment Type

5.3.1 Allogeneic Stem Cell Therapy

5.3.2 Auto logic Stem Cell Therapy

5.3.3 Syngeneic Stem Cell Therapy

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia-Pacific

5.4.4 Middle-East & Africa

5.4.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Osiris Therapeutics Inc.

6.1.2 Pluristem Therapeutics Inc.

6.1.3 Thermo Fisher Scientific

6.1.4 Merck KGaA (Sigma Aldrich)

6.1.5 Becton, Dickinson and Company

6.1.6 Stem Cell Technologies Inc.

6.1.7 AllCells LLC

6.1.8 Miltenyi Biotec

6.1.9 International Stem Cell Corporation

6.1.10 Smith & Nephew PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/z5sdky

Original post:
Global Stem Cell Market Study and Forecast 2020-2025: Oncology Disorders Expected to Exhibit the Fastest Growth Rate - ResearchAndMarkets.com -...

2020 World Sickle Cell Day: Symptoms of sickle cell can appear around 5 months of age

World Sickle Cell Day is observed on June 19. The day is meant to raise awareness about sickle cell disease, which is a group of disorders that affect haemoglobin, the molecule in red blood cells which deliver oxygen to cells throughout the body. People with this disorder have haemoglobin S, an atypical haemoglobin molecule which can distort red blood cells into a sickle or a crescent shape. This disease is a blood disorder which is inherited and passed down from parents to the child. In 2008, the UN General Assembly recognised sickle cell disease as a public health problem, and one of the world's foremost genetic diseases.

Symptoms of sickle cell disease usually appear around five months of age. The symptoms vary from person to person and change over time.

Symptoms of sickle cell disease can appear from two to five months of age. But in milder cases, the symptoms may appear till teenage.

Sickle cell disease can cause vision problemsPhoto Credit: iStock

Also read:These Iron-Packed Foods Can Combat Anemia And Other Health Problems

One can get infected with sickle cell disease if both parents have the problem gene and pass it on to their child.

1. HbSS or sickle cell anemia is a severe kind of sickle cell disease. It occurs when child inherits sickle cell gene from each parent.

2. HbSc occurs when one parents has sickle cell gene and the other has a gene from abnormal haemoglobin.

3. Hbs beta thalassemia occurs when sickle cell gene is passed from one parent, and beta-thalassemia is passed on from the other.

If only one parent has the problem gene, then the child will not have symptoms but will have the gene known as sickle cell trait.

Also read:Anemia During Pregnancy: Symptoms, Risk Factors And Prevention Steps Every Woman Must Know

Sickle cell can be detected in an infant during newborn screening process. In case of family history, it can be detected during pregnancy.

Bone marrow or stem cell transplant is the only permanent cure for sickle cell disease. Early detection and timely treatment can help in managing symptoms, offer relief from pain and prevent severe complications.

Apart from stem cell transplant, the symptoms can be managed with the help of periodic blood transfusion, pain killers, vaccinations and antibiotics.

Also read:6 Side-Effects Of Overuse Of Antibiotics And Home Remedies By Rujuta Diwekar That Can Be As Effective

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

See more here:
World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment - NDTV

In order to understand how COVID-19 spreads throughout the body, ravaging it in myriad ways, doctors are growing miniature balls or organ-like tissue called organoids, and infecting them again and again.

The results, Nature News reports, are particularly troubling: the miniature lungs, livers, kidneys, hearts, intestines all showed signs of damage. The series of studies reveals with shocking clarity that COVID-19 can cause far more than a lung infection.

Of course, thats not exactly news. This harrowing list of survivors and medical workers horror stories gathered by SFGate includes heart attacks, strokes, long-term lung damage, incontinence, skin damage, and other serious complications for supposed mild cases of the coronavirus:

Thats just one of the many, many stories they gathered about the ways a road to recovery from COVID-19 is neither linear nor something that shouldnt be feared.

That said, for all their benefits, organoids are still imperfect. Per Nature, theyre far more simplistic than a full-sized organ. And because theyre not all connected in the same body, doctors can only use them to study the impacts on a single organ in isolation.

We know the cells die but we dont know how, Weill Cornell Medicine stem cell biologist Shuibing Chen told Nature of her study on miniature lungs.

Even though questions remain, its clear those impacts are serious. Various studies found that the coronavirus caused serious damage in several organs, and may lead to indirect damage in others. It also became clear that the coronavirus can infect and spread through blood vessels, leading to a more serious, widespread case.

To figure that out, biologists will need to develop more sophisticated and realistic organoids and try their experiments again, Nature reports.

It is too early to say how relevant they are, Bart Haagmans, an Erasmus MC virologist who ran a study on gut organoids, told Nature.

Original post:
Mini-Organ Research Reveals What COVID-19 Does to the Body - Futurism

Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders

High precision cell therapies manufactured by Orca Bio have the potential to replace conventional bone marrow transplants and expand the eligible patient population

$192 million Series D financing strengthens the company with resources to propel lead product candidate to completion of clinical development

MENLO PARK, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- Orca Bio, a clinical-stage biotechnology company developing high precision allogeneic cell therapies, today announced a Series D financing that brings its total capital raised since its 2016 launch to nearly $300 million. The company creates precisely controlled cell therapies by building each dose cell-by-cell from another persons blood. Each therapy is constructed by formulating a proprietary mixture of cells that aims to cure the patients disease and eliminate dangerous side effects.

Orca Bios $192 million Series D financing was co-led by Lightspeed Venture Partners and an undisclosed investor. Other new and existing blue-chip investors also participated in the latest round, including 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust and IMRF.

The financing will support the continued advancement of Orca Bios cell therapy pipeline and its novel manufacturing platform, which sorts blood with single-cell precision and a high level of purity and speed to create optimal therapeutic mixtures of immune and stem cells. These proprietary mixtures have the potential to revolutionize allogeneic cell therapy for hematological and other cancers, as well as many other diseases and disorders.

A conventional bone marrow transplant relies on naturally occurring T cells. However, the uncontrolled cellular composition often results in life-threatening complications. The companys most advanced program, TRGFT-201, is evaluating a highly controlled formulation of T cells that includes subsets of regulatory T cells, in a Phase I/II clinical study in patients with certain blood cancers. The companys second program, OGFT-001, is evaluating a fully controlled cell product candidate that contains a next-generation formulation of T cells, in a Phase I study, also in patients with blood cancers. Orca Bios two ongoing clinical studies are among the largest Phase I cell therapy trials ever conducted. Each product candidate has the potential to deliver curative outcomes for the initial indications Orca Bio is pursuing, as well as the promise to significantly expand the eligible patient population by substantially reducing the severe toxicities associated with conventional bone marrow transplants.

The capital we have raised has formed the launch pad for a world-class, fully integrated allogeneic cell therapy company differentiated from all others, said Ivan Dimov, PhD, Co-founder and Chief Executive Officer of Orca Bio. Replacing bone marrow transplants is a logical first step in next-generation allogeneic cell therapy. While a conventional bone marrow transplant administers an uncontrolled cell product, Orca Bio has been the first to deliver a high precision cell therapy. We are initially focused on advancing two clinical programs in patients with blood cancers and have successfully treated the largest-ever number of patients with a high precision cell therapy. We believe our approach has the potential to transform allogeneic cell therapy, and thus the treatment of not only blood cancer, but also many other diseases with significant unmet need, such as a variety of genetic diseases and autoimmune disorders.

With precise reconstitution using highly defined cell preps and a swift reboot of the patients immune system, Orca Bios product candidates have the potential to eliminate fatal side effects, such as graft-versus-host disease, and infections commonly associated with bone marrow transplants while maintaining or enhancing anti-tumor efficacy, said Rick Klausner, MD, an investor and member of Orca Bios advisory board. The possibility of improving cure rates and minimizing toxicity holds the promise of expanding the eligible patient population for successful bone marrow transplantation in cancer.

Orca Bios visionary leadership team, seasoned advisors, solid financial foundation and novel technology make the company uniquely suited to develop truly differentiated, scalable allogeneic cell therapies, said Jonathan MacQuitty, PhD, Venture Partner at Lightspeed Venture Partners. I look forward to the Orca Bio teams continued development and commercialization of revolutionary allogeneic cell therapies.

Internationally Recognized Experts and Leaders

Orca Bios leadership, Ivan Dimov, PhD, Chief Executive Officer, Nate Fernhoff, PhD, Chief Scientific Officer, and Jeroen Bekaert, PhD, Chief Operating Officer, met at Stanford University and launched the company in 2016. Orca Bios board of directors and advisory board are comprised of renowned scientific leaders and seasoned biotech executives with extensive experience in drug discovery and cell-based therapeutics, including:

About Orca Bio

Established in 2016, Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely and effectively replace a patients blood and immune system with a healthy one. The companys proprietary therapeutic and manufacturing platforms are exclusively licensed from Stanford University. The manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling the creation of proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. The companys lead product candidate is being evaluated in a multi-center Phase I/II clinical trial in patients with blood cancers. For more information, please visit http://www.orcabio.com.

Media Contact: media@orcabio.com

Originally posted here:
Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy - GlobeNewswire

Two small studies published recently suggested most men hospitalised with COVID-19 are bald, generating headlines around the world.

While this may sound strange, science does offer a plausible explanation.

Male pattern baldness is associated with high levels of male sex hormones called androgens. And androgens seem to play an important role in the entry of SARS-CoV-2, the coronavirus that causes COVID-19, into cells.

So its possible high levels of androgens might increase the risk of severe infection and death from COVID-19.

This hypothesis is important to identify people at risk and raises the possibility of new treatment strategies for COVID-19.

Read more: Why do more men die from coronavirus than women?

Its been obvious from early in the pandemic. Men are at greater risk of severe infection and death from COVID-19 than women.

There are several possible factors at play here. For one, men are more likely to suffer from chronic conditions known to pose a higher risk of serious illness from COVID-19. These include heart disease and diabetes.

Another is that mens immune systems are not as good as womens at warding off the severe effects of viral infections.

These factors are indirectly influenced by sex hormones. Now it seems sex hormones might also have a direct effect on SARS-CoV-2s ability to enter our cells and establish infection.

In one study of 122 male COVID-19 patients admitted to hospitals in Madrid, 79% were bald about double the population frequency.

Another small study in Spain observed a similar overrepresentaton of baldness among men hospitalised with COVID-19.

Read more: Starting to thin out? Hair loss doesn't have to lead to baldness

Male pattern baldness is strongly associated with a higher level of dihydrotestosterone (DHT), a more active derivative of testosterone, and one of the androgen family of male sex hormones.

Confirming this correlation between baldness and susceptibility to COVID-19 with larger samples, controlling for age and other conditions, would be significant. It would suggest a higher DHT level could be a risk factor for severe COVID-19.

SARS-CoV-2 enters human lung cells when a protein on the virus surface (the spike protein) latches onto protein receptors (ACE2 receptors) embedded in the cells surfaces.

How does this work? Recently scientists discovered that an enzyme called TMPRSS2 cleaves the SARS-CoV-2s spike protein, enabling it to bind to the ACE2 receptor. This allows the virus to enter the cell.

The gene that encodes TMPRSS2 is activated when male hormones, particularly DHT, bind to the androgen receptor (a protein on the surface of cells, including hair cells and lung cells).

So the more male hormone, the more androgen receptor binding, the more TMPRSS2 is present, and the easier it is for virus to get in.

A preliminary, non-peer-reviewed study which correlated the androgen levels of hundreds of people in the UK with COVID-19 severity supports this theory. Higher androgen level was associated with susceptibility to and severity of COVID-19 in men (but not women, who have much lower androgen levels in their blood).

The same researchers showed that inhibiting androgen receptors reduced the ability of SARS-CoV-2s spike protein to bind to ACE2 receptors on stem cells in culture.

Over- or underproduction of androgens in the body causes a variety of conditions in both men and women.

For instance, men with benign prostate enlargement overproduce androgen, as do women with polycystic ovary syndrome.

Many such conditions are treated with androgen deprivation therapy (ADT), which inhibits the production or effect of androgens. For instance, prostate cancer, in which cancer cell growth is fuelled by androgens, is routinely treated with ADT.

Conversely, some people have low androgen production, or mutations that affect the binding and action of androgens such as women with androgen insensitivity syndrome caused by mutations of the androgen receptor.

It will be important to find out whether, as the androgen hypothesis predicts, patients with over- or under-production of male hormones are at greater or lesser risk of COVID-19.

Read more: How can I treat myself if I've got or think I've got coronavirus?

If the androgen link holds up, this would encourage exploration of anti-androgens as a way to prevent and treat COVID-19.

Many anti-androgens are already approved for the treatment of other conditions. Some, like baldness treatments, have been used safely for years or decades. Some, like cancer treatments, can be tolerated for months.

A study which looked at men hospitalised with COVID-19 in Italy showed the rate of infection was four times lower in prostate cancer patients on ADT than in untreated cancer patients.

Perhaps a single dose given to someone who tests positive to SARS-CoV-2, or has just been exposed, would suffice to lower the chance of the virus taking hold.

But we need research to confirm this. Several androgen-suppressing drugs are now undergoing clinical trials to determine whether they reduce complications among men with COVID-19.

It will be important to verify that anti-androgen treatment works in the lungs as well as the prostate, and is effective in cancer-free patients. Wed also need to find out what dose is effective, and when it should be administered.

Anti-androgen treatments have several side effects in men, including breast enlargement and sexual dysfunction, so medical oversight is a must.

The androgen link could go a long way to explaining why men are more susceptible to COVID-19 than women. It also may explain why children younger than ten seem very resistant to COVID-19 because, until puberty, boys as well as girls make little androgen.

The more we know about who is at heightened risk from COVID-19, the better we can target information.

The androgen link also opens up an avenue for the discovery of drugs which might mitigate some of the impact of COVID-19 as it continues to sweep the globe.

Read more: COVID-19's deadliness for men is revealing why researchers should have been studying immune system sex differences years ago

Read more:
Coronavirus and sex hormones baldness may be a risk factor and anti-androgens a treatment - The Conversation AU

Billion Dollar Burger: Inside Big Tech's Race for the Future of Food, by Chase Purdy Portfolio hide caption

Billion Dollar Burger: Inside Big Tech's Race for the Future of Food, by Chase Purdy

What is meat? You might say it's simple: water, fat, muscle, connective tissue you know, all that tasty-sounding stuff.

But those at the forefront of developing cell-cultured meat have a different idea. Maybe meat is the product not of killing animals but of cultural consensus.

At the center of Chase Purdy's briskly paced and quietly bold Billion Dollar Burger: Inside Big Tech's Race for the Future of Food is Josh Tetrick, a San Francisco-based entrepreneur and CEO of Just Inc. Tetrick's company and a handful of others like it are growing cell-cultured meat that tastes, feels and looks like the livestock-harvested meat that people are used to except without the farms and killing of animals. And before anyone raises a skeptical brow: Yes, it's actually meat. Technically, at least. The struggle for mainstream acceptance of cell-cultured meat is real. Convincing the American public that cells grown in "serum" in a big vat is meat will be challenging, but it could happen and sooner than you might think.

Meat, it seems, is all about what consumers are used to. For the sake of the planet and the future of food sustainability, it might be time to reconsider meat harvested from dead animals. If we're going to eat meat at all, eliminating the need to kill an animal that consumes food resources humans could otherwise be using and that's also captive to an industry that pollutes the air and soil and deforests broad swaths of the planet might be a good start.

One of Purdy's strengths is his ease in exposition. He can even be charmingly teacherlike at times. Take, for instance, how he describes how cell-cultured meat is grown, starting with cells taken from a live animal.

"The scientists at cell-cultured meat companies identify which cells are stem cells. Whereas ordinary cells have limited utility, stem cells can divide and multiply many times, and they can transform into any of the more than two hundred types of cells that operate within animal bodies.

Think of our cells as individuals on a building construction site. Some are assigned to lay cement, some are trained as carpenters, and another might be an electrician. Together, they work harmoniously to build different components of the larger structure. But it is possible to pluck a cement worker from her job, send her to classes where she'll learn about wiring, plugs, and sockets. Then she can be sent back into the field as a newly trained electrician. The same thing can happen on a molecular level."

That's not all though. Scientists grow those cells in a kind of liquid. Because lab-grown meat doesn't have blood to circulate nutrients like living bodies do, scientists at Just and companies like it use a kind of "serum" that contains sugars, lipids, hormones and amino acids, as well as many hundreds of proteins that carry out functions such as transporting insulin, which helps grow cultured vertebrate cells, or transferrin, which delivers iron to cells. Oh, and all this takes place in vats that can look straight out of a brewery.

In covering the business side of cell-cultured meat, Purdy could have written a hagiographic account of Tetrick and Just; refreshingly, he chose not to. This could have been another Steve Jobs-type story no one needs, where a visionary has a great idea that will change the world and then, after the world gets changed wait for it said visionary gets really rich too. Then, as Americans, we're left undecided as to whether we admire the accomplishment or the wealth more. Instead, Purdy's book reads more realistically, like the teasing out of a tangled dance among entrenched meat producers, a few ambitious start-ups, early pioneers, regulatory complications and consumer skepticism.

It's the lack of heroes that, in part, makes this such an interesting story and topic. Tetrick knew from his early years that he cared about animal welfare and that he wanted to do something good for the world. He drifted through law school and still was unsure about a proper course for his life. He decided on cell-cultured meat as a cause and business because he saw opportunity and it aligned with his values and so he decided to take it. And in the depiction of Tetrick, Purdy is careful to allow him to tell his story, as well as capture others' stories of him, some of which are unflattering. Meat, however, stays front and center in this story. It keeps you hungry.

Still, there's the moral and ethical matter of manipulating nature to serve human ends. Sure, other forms of this kind of manipulation go by the names "civilization" or "technology," but the issues arising from cell-cultured meat aren't minor. Essentially it's cloning. Purdy asks Peter Singer, a Princeton University bioethics professor and the author of Animal Liberation, whether growing meat in vats violates the natural order and if he has a problem with it. "No, I don't, to be honest," Singer says. "I think we can and always have striven to do better than nature. ... I don't think nature is in any way a gold standard."

Alice Waters, famous chef of Chez Panisse in Berkeley, Calif., sees things differently. She tells Purdy: "I really think of my food as deeply connected to nature. It has to do with seasonality; it has to do with a complexity of soil that grows the vegetables that the animals eat. I think it's what nourishes us." This might be true, but most people don't (and can't) get their meat locally sourced, even if that would be ideal. Sustainable consumption of meat might just require more cell-cultured meat than its livestock-harvested antecedent.

Purdy rightly leaves the humans vs. nature debate aside, though, after teasing out the positions, and gets back to the big question: What is meat? Philosopher Friedrich Nietzsche wrote that "there is no feast without cruelty," but he clearly did not live to see the still ambiguous but encouraging promise of cell-cultured meat. Meat, oddly enough, might just be what we agree meat is. Heretofore it was the flesh of a dead animal. Now it can be engineered in a lab to have the same properties that a living animal's flesh would have.

If the taste and texture are the same and if the cost is manageable, why not? Now, when someone says, "It tastes like chicken," you can say: "It is chicken." It's grilling without the killing.

Nicholas Cannariato is a writer and editor based in Chicago.

See original here:
What Is Meat?: 'Billion Dollar Burger' Looks At The Future Of Food - NPR

SINGAPORE: About nine months ago, doctors in the UK told Oscar Saxelby-Lees parents there was nothing more they could do for him all treatment options had been exhausted and there was only palliative care left for the little boy.

But after coming to Singapore for anexperimental treatment for acute lymphoblastic leukaemia, Oscar is now almost ready to go home after receiving news on Monday (Jun 15) he has been free of cancer for almost six months.

Since he was diagnosed in December 2018, he hasundergone rounds of chemotherapy, months in isolation, several stem cell transplants and a treatment in Singapore that only one other child in the world has received.

The six-year-old is set to undergo a check up later this week, and will hope to be given the all clear to fly home, his mother Olivia told CNA.

Hes like our little miracle. Its incredible, I couldnt express to you the feelings were feeling now, she said.

As long as all is okay and nothing needs to happen, or nothing needs to be changed, then we should be ready to go (home), which is incredible and for Oscar, is everything.

Hes a little boy who wants to experience life and to most of all, be with his family. He is really excited about it."

Going home will bringits own difficulties.

It is a huge step to go back. Singapore is our security net, and thats why its so hard for us as parents to kind of pack up and go and leave, Olivia explained.

I say a security net for us because when we go home, if anything were to happen to Oscar we are kind of worried because if anything did happen, where would you go?

But to just see our family again we are desperate just to get home to see people, just to see them.

"I know at the moment it is difficult, but just to have a cuddle, or you know, some support in front of us rather than over the phone or virtually its a real hard situation to be in.

COMPASSIONATE TREATMENT WAS LAST HOPE

The treatment atNUH was Oscars last hope. In the UK, doctors had battled for months to rid his body of the cancer.

But despite a stem cell transplant and four rounds of chemotherapy that left him very weak, the leukaemia kept coming back.Doctors told his parents there was no other treatment, and that the cancer would take his life.

The little boy from Worcester, England flew to Singapore after the family crowdfunded 500,000 (S$885,000) for a new form of treatment, in which immune cells from a patients blood aredrawn and equipped with a Chimeric Antigen Receptor (CAR-T).

The receptor binds itself to a specific protein on the cancer cell and activates the CAR-T cells to kill the cancer cells.

This particular form of CAR-T treatment is different and more difficult because the leukaemia cells resemble Oscars immunity system, Associate Professor Allen Yeoh, head of paediatric oncology at NUH, explained previously.

Oscar started treatment on Christmas Eve last year and three weeks later, was given the best news that there were no detectable cancer cells in his body the first major step. But there were always concerns the cancer could make a comeback, as it did previously.

Diseases like Oscars are really reluctant to give up, theyre quite vile, Olivia said. It gets progressively nasty.

IT HAS BEEN RELENTLESS

Over the last few months, Oscar has battled several conditions as a result of complications and undergone more surgeries and transplants.

He was diagnosed with both Graft versus host disease (GvHD) and Thrombotic microangiopathy(TMA) that caused him shaking spells, pain and weakness.

Brain damage also caused him problems with his mobility, and he uses a frame or needs a hand to walk.

Some of the side effects of the treatment have been relentless, Olivia said, adding that Oscar suffers from sickness, diarrhea, mood swings and mobility issues.

Hes had really bad tremors since he was diagnosed with brain damage post CAR-T (treatment). But he has done amazingly well with it, she said.

Hes had numerous side effects. It goes from something as simple as hair loss to, you know, real damage to the body. Oscar has struggled immensely from his mobility.

He's very frail, his legs are very weak. He is only just managing to walk without a (walking) frame.

Oscar was discharged just days after Singapore implemented a circuit breaker to curb the spread of COVID-19, and he has been battling the tremors while staying in.

Hes walking with a parents hand, or just about, maybe taking a couple of steps. Its like training a toddler again, and its really hard.

He's come so far but yet he's got so much to cope with on top. It's so hard.

But for Oscar, battling to get back on his feet is not new. When he first arrived in Singapore in November last year, he was so weak from the rounds of chemotherapy and months in isolation that bruises developed on his legs when he walked.

He manages to plow through, he's such a trooper. He really is in an inspiration to us.

It is a huge mountain of accomplishment for the six-year-old boy, Olivia said. We continue to remind him everyday of how far hes come, and how far he will go.

Olivia said they are "so grateful"to the medical staff at NUH for saving Oscars life.

The teams have been incredibly strong with us, and theyve supported our every decision, she said. They are just incredible."

She thanked Dr Frances Yeap, a consultant in paediatric oncology at the hospital and Prof Yeoh, who actually made us come here and forget about everybody elses opinion.

The nurses in Ward 8B at the hospital have also been a source of support for them, Olivia said.

They are a great team and the nurses. The consultants and the team have never doubted Oscar. We are so grateful. They have saved Oscars life.

Read more from the original source:
British boy who came to Singapore for treatment for aggressive cancer is 'almost ready to go home' - CNA

The process is relatively straightforward and will only take between 30mins and 4 hours to complete. You will be carefully monitored during your stem cells infusion.

Your treating team will monitor you very closely in the days following your transplant. They will take your blood often to ensure your body has accepted the new stem cells and the stem cells are doing their job in your bone marrow.

Infections are common after a stem cell transplant due to the high dose therapies you receive in the lead up. If you have a fever (feeling very hot or cold or are shivering) you should alert your doctor or nurse immediately.

Please see Stem Cell Transplants and Infection Prevention for important information for patients and visitors.

There are several conditions that are commonly associated with high dose chemotherapy and radiotherapy, or with the transplant itself. There is also a risk with allogeneic transplant that your new stem cells will not engraft, however this is rare. Your treating team will take every precaution to prevent these and monitor you closely to ensure they are quickly detected and treated.

You treating team will discuss with you at length any complications associated with both autologous and allogeneic stem cell transplantation. If you experience any new symptoms you should alert your doctor or nurses immediately.

Please see Treatment Related Side Effects for other common side effects from treatment.

It will take some time to recover from a stem cell transplant. It varies from person to person and is dependent on your disease, the other treatments you received and any complications you may have experienced.

Generally speaking recovery takes:

When you leave hospital you will still need to return regularly to monitor the progress of your transplant and your general well-being.

If it is a medical emergency call 000

If you have any of the following symptoms please contact Peter Mac straight away and ask for the registrar on call, on (03) 8559 5000:

If you present to an emergency department, please ensure you let them know immediately that you have had a stem cell transplant and do not wait in the emergency cue.

This content was adapted from the Leukaemia Foundation's Guides for Patient and Families.

Here is the original post:
Recovery and complications of stem cell transplants ...

COVID-19 impact will also be included and considered for forecast.

Global Autologous Stem Cell and Non Stem Based therapies Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Autologous Stem Cell and Non Stem Based therapies Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=70&RequestType=Sample

Brandessence Market Research is working on a new report titleAutologous Stem Cell and Non Stem Based therapies Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?.Rise in the prevalence of Cancer and Diabetes in all age groups population. Furthermore, the growing geriatric population is another key factor which drives the Autologous Stem Cell and Non Stem Based therapies Market.

Autologous Stem Cell and Non Stem Based therapies Market Reports

Autologous Stem Cell transplantation is a process in which cells from which all blood cells develop are removed, preserved and later given to the same person after severe treatment. In autologous stem cell transplantation, the patient itself acts as stem cell donor. These cells are collected in advance while they are in remission and returned to the patient at a later stage i.e., after two months. They are used to replace stem cells which have been impaired by high doses of chemotherapy.It is important to realize that the processes required in a stem cell transplant are lengthy and complicated. A transplant involves a lot of preparation and a lot of care after procedure. Many people have a single autologous stem cell transplant while othersmainlyhaving myeloma or tumors; have two or more continuous transplants.

The initial step in an autologous stem cell transplant is gathering the stem cells. Physicians usually collect stem cells from the bloodstream (peripheral blood stem cells) in advance. A mobilization treatment is used. When the stem cells are in the bloodstream, then collection process starts.The blood is separated using an Apheresis machine. This procedurerequires a few hours, and is repeated until the appropriate amount of stem cells is collected. Once the stem cells are harvested, they are frozen in our Stem Cell Processing and Cryopreservation Laboratory until its time to transplant.

Autologous Stem Cell and Non Stem Based therapies Market is segmented on the basis of Application, product, End user and Geography. Based upon ApplicationAutologous Stem Cell and Non Stem Based therapies Market is classified as Neurodegenerative Disorders,Autoimmune Diseases, cancer &Tumors, Cardiovascular Diseases and Others. Based on the ProductAutologous Stem Cell and Non Stem Based therapies Market is classified into Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices and Intracranial Pressure Monitoring Devices. On the basis of End users Autologous Stem Cell and Non Stem Based therapies Market is classified into Hospitals, Ambulatory Surgical Centers and Others.

The regions covered in Autologous Stem Cell and Non Stem Based therapies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Autologous Stem Cell and Non Stem Based therapies Market Reports :Autologous Stem Cell and Non Stem Based therapies Marketreports cover prominent players likeBioheart, Antrie Inc., Virxsys, Brainstorm Cell Therapeutics, TiGenix, Cytori Therapeutics Inc.,Tengion Inc.,Dendreon Corporation, Regeneus, Fibrocell, Genesis Biopharma, Orgenesis, Opexa Therapeutics,Neostem, U.S. Stem Cell Inc.,Vericel Corporation, Sanofi, IovanceBiotherapeutics Inc., Mesoblast Ltd., pluristem, Med Cell Europe AG, Anova IRM Stem Cell Center, Stemedica Cell Technologies Inc.,General Electric Company, BioRestorative Therapies,StemGenexamong,Aastrom Biosciences,NeoStem, Inc.,Virxsys, Genzyme Corporation and Georgia Health Science University.

Autologous Stem Cell and Non Stem Based therapies Market Dynamics

Rising prevalence of cancer and diabetes among people across all age groups, growing geriatric population, increasing demand for autologous stem cell and non-stem cell based therapies is another factor, which is likely to create a heightened demand. Moreover, Favorable reimbursement policies across several nations are also boosting market. Risks and complications associated with the Autologous Stem Cell and Non Stem Based therapy such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility and thehigh cost of autologous cellular therapies ranging from $500,000 to $1,000,000 restraint the market. Innovation of some newtherapies with improved efficacy, fewer side effects are expected to offer good opportunity for growth of Autologous Stem Cell and Non Stem Based therapies Market in the future.

Autologous Stem Cell and Non Stem Based therapies Market Regional Analysis North America is probable to attain the largest share of the Autologous Stem Cell and Non Stem Based therapies Market in terms of revenue and expected to hold the position followed by Europe region. This is due to less risk related with the treatment. Also, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not require an outside donor hence the treatment is less infectious and cheap. However, Asia Pacific is expected to show the high growth in the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Rising healthcare facilities as well as increasing tax and reimbursement procedures is also estimated to help in the growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific.

Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

Key Benefits for Autologous Stem Cell and Non Stem Based therapies Market Reports

Autologous Stem Cell and Non Stem Based therapies Market report covers in depth historical and forecast analysis.Autologous Stem Cell and Non Stem Based therapies Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Autologous Stem Cell and Non Stem Based therapies Market report helps to identify opportunities in market place.Autologous Stem Cell and Non Stem Based therapies Market report covers extensive analysis of emerging trends and competitive landscape.Autologous Stem Cell and Non Stem Based therapies Market Segmentation Autologous Stem Cell and Non Stem Based therapies Market: By Application AnalysisNeurodegenerative DisordersAutoimmune Diseasescancer & TumorsCardiovascular DiseasesOthersAutologous Stem Cell and Non Stem Based therapies Market: By Product AnalysisBlood Pressure Monitoring DevicesPulmonary Pressure Monitoring DevicesIntracranial Pressure Monitoring DevicesOthersAutologous Stem Cell and Non Stem Based therapies Market: By End User AnalysisHospitalsAmbulatory Surgical centersOthersAutologous Stem Cell and Non Stem Based therapies Market: By Regional & Country AnalysisNorth AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=70&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Autologous Stem Cell and Non Stem Based therapies Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Autologous Stem Cell and Non Stem Based therapies Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Autologous Stem Cell and Non Stem Based therapies Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Autologous Stem Cell and Non Stem Based therapies Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Autologous Stem Cell and Non Stem Based therapies Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Autologous Stem Cell and Non Stem Based therapies Market.

Market Forecast: Here, the report offers a complete forecast of the Global Autologous Stem Cell and Non Stem Based therapies Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Follow this link:
2025 Projection: Autologous Stem Cell and Non Stem Based therapies Market 2020 by Product, Application, Manufacturer, Sales and Segmentation 2026 -...

With a full devotion and dedication this superior GLOBAL HUMAN EMBRYONIC STEM CELL MARKET report is presented to the clients that extend their reach to success. Market parameters covered in this advertising report can be listed as market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. Each parameter included in this GLOBAL HUMAN EMBRYONIC STEM CELL MARKET business research report is again explored deeply for the better and actionable market insights. Geographical scope of the products is also carried out comprehensively for the major global areas which helps define strategies for the product distribution in those areas.

TheGlobal Human Embryonic Stem Cell Marketstudy with 100+ market data Tables, Pie Chat, Graphs & Figures is now released by Data Bridge Market Research. The report presents a complete assessment of the Market covering future trend, current growth factors, attentive opinions, facts, and industry validated market data forecast till 2026. Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share ofMajor Players such as Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc and amny More

Global human embryonic stem cell market estimated to register a healthy CAGR of 10.5% in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the increase in tissue engineering process.

Avail 20% Discount on Buying This Report: Get a Free Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-embryonic-stem-cell-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Human Embryonic Stem Cell Market By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), End User (Research, Clinical Trials, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Global Human Embryonic Stem Cell Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Human Embryonic Stem Cell Industry

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-human-embryonic-stem-cell-market

The titled segments and sub-section of the market are illuminated below:

By Type

By Application

By End User

Top Players in the Market are:

Some of the major companies functioning in global human embryonic stem cell market are Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc, Waisman Biomanufacturing, Caladrius, Pfizer Inc., Thermo Fisher Scientific, Merck KGaA, Novo Nordisk A/S, Johnson & Johnson Services, Inc and SA Biosciences Corporation among others.

How will the report help new companies to plan their investments in the Human Embryonic Stem Cell market?

The Human Embryonic Stem Cell market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Human Embryonic Stem Cell Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Human Embryonic Stem Cell Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

See the original post:
GLOBAL HUMAN EMBRYONIC STEM CELL MARKET Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth, Business...

Treatment with plinabulin in combination with pegfilgrastim (Neulasta) achieved the primary end point and several key secondary end points in the phase 3 PROTECTIVE (Study 106) clinical trial, which evaluated the combination compared with pegfilgrastim alone for superiority in chemotherapy-induced neutropenia prevention, according to the interim results announced by BeyondSpring, developer of the drug.

These results demonstrate significant enhancement to granulocyte colony-stimulating factors (G-CSFs) with the combination compared with pegfilgrastim alone for the prevention of grade 4 or severe neutropenia, supporting the potential for superiority with the combination compared with pegfilgrastim alone.

These interim results from the PROTECTIVE-2 Phase 3 study, which compares the Plinabulin-Neulasta combination to Neulasta alone, have the potential to be clinically meaningful for cancer patients receiving chemotherapy, stated Douglas W. Blayney, MD, professor of Medicine at Stanford Medical School and global principal investigator of Plinabulins chemotherapy-induced neutropenia studies. Since most infections, hospitalizations, and other complications of chemotherapy-induced neutropenia occur in the first week after chemotherapy, it is particularly gratifying to see the combinations clinical benefit demonstrated.

The primary end point was the rare of severe neutropenia prevention in cycle 1 (P <.01). The key secondary end points included duration of severe neutropenia in cycle 1 (P <.05) and duration of severe neutropenia in the first 8 days of cycle 1 (P <.05). The achievement of these end points demonstrates the agents ability to provide early protection against severe neutropenia induced by chemotherapy.

The interim analysis of the double-blind, active-controlled, global PROTECTIVE-2 study was pre-specified for the first 120 patients accrued. The study also has procedures in place for the prevention of potential bias after the planned interim analysis, and BeyondSpring opted to be informed by independent statisticians on whether the pre-specified P values were met rather than the exact P values.

The study was designed to assess both the safety and efficacy of plinabulin in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide (TAC) in a 21-day cycle. Plinabulin was administered in a 40 mg dose on day 1 with a 6 mg dose of pegfilgrastim on day 2, while pegfilgrastim was administered at the same 6 mg dose on day 2 in the control arm. TAC is considered a high-risk chemotherapy regimen associated with neutropenia.

PROTECTIVE-2 is a superiority study for chemotherapy-induced neutropenia efficacy compared with pegfilgrastim alone and is currently enrolling patients. Grade 4 neutropenia rate for TAC and pegfilgrastim is observed in 83% to 93% of patients, which represents a severe unmet medical need.

The study drug and G-CSF have complementary mechanisms of action for preventing chemotherapy-induced neutropenia. Plinabulin is a first-in-class differentiated immune and stem cell modulator, which is currently in late-stage clinical development as a potential treatment for increasing overall survival in patients with cancer in addition to its ability to alleviate chemotherapy-induced neutropenia.

Plinabulin is also under evaluation in a phase 3 study as a direct anticancer drug as treatment of patients with nonsmall cell lung cancer and 2 phase 3 studies for the prevention of chemotherapy-induced neutropenia. The data for this agent in preventing chemotherapy-induced neutropenia highlights its ability to boost the number of hematopoietic stem or progenitor cells (HSPcs), as well as lineage-/cKIT+/Sca1+ cells in mice. Plinabulins effects on HSPcs may explain its ability to treat chemotherapy-induced neutropenia as well as its ability to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34-positive cells.

To be included in the study, patients should be candidates for TAC in either the adjuvant or neoadjuvant setting, have early-stage breast cancer, and have received no prior chemotherapy. Patients must also have an ECOG performance status of 0 or 1 and a life expectancy of at least 3 months. Patients cannot be included in the study if they have a history of myelogenous leukemia, myelodysplastic syndrome, or sickle cell disease; use of CYP3A4, CYP2D6 or P-glycoprotein inhibitors and inducers within 14 days prior to receiving the study drug; or have received an investigational agent or tumor vaccine within 2 weeks, any concurrent anticancer therapies, or a bone marrow or stem cell transplantation.

These results could help to confirm the patient benefit of Plinabulins different mechanism of action from the G-CSF-based agents, such as Neulasta, Blayney stated. Plinabulin appears to have chemotherapy-induced neutropenia protection in Week 1, and G-CSFs have protection in Week 2 of chemotherapy cycles. The combination should logically provide significantly better protection than Neulasta alone as shown in the interim readout. We are well on our way to confirming that the combination offers protection throughout the chemotherapy cycle, which is an unmet medical need.

Reference

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention. NewsRelease. BeyondSpring. June 15, 2020. Accessed June 15, 2020. https://bit.ly/2YDJbiQ

Read the original post:
Plinabulin Combo May Be Superior Therapy for Prevention of Chemotherapy-Induced Neutropenia - Targeted Oncology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy for adult and adolescent patients with sickle cell disease (SCD) show a near-complete reduction of serious vaso-occlusive crises (VOCs) and acute chest syndrome (ACS). These data are being presented at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress.

Vaso-occlusive crises (VOCs) are the painful, life-threatening episodes that are the primary clinical manifestation of sickle cell disease. The nearly complete elimination of VOCs that we saw in this study is impressive and demonstrates the potential of LentiGlobin for SCD as a treatment for this serious disease, said David Davidson, M.D., chief medical officer, bluebird bio. These results illustrate the type of outcomes we believe are needed to provide truly meaningful improvements for people living with sickle cell disease. In addition, the improvement of laboratory measures of hemolysis and red cell physiology, with nearly pan-cellular distribution of the anti-sickling HbAT87Q, suggest LentiGlobin for SCD may substantially modify the causative pathophysiology of SCD. We are pleased to have reached a general agreement with the FDA on the clinical data required to support a submission for LentiGlobin for SCD and we plan to seek an accelerated approval. We look forward to working with the entire SCD community to bring forward a disease modifying option for patients.

SCD is a serious, progressive and debilitating genetic disease caused by a mutation in the -globin gene that leads to the production of abnormal sickle hemoglobin (HbS). HbS causes red blood cells to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and unpredictable, painful VOCs. For adults and children living with SCD, this means painful crises and other life altering or life-threatening acute complicationssuch as ACS, stroke and infections. If patients survive the acute complications, vasculopathy and end-organ damage, resulting complications can lead to pulmonary hypertension, renal failure and early death; in the U.S. the median age of death for someone with sickle cell disease is 43 - 46 years.

As a physician treating sickle cell for over 10 years, the excruciating pain crises that my patients suffer from is one of the most challenging and frustrating aspects of this disease, said presenting study author Julie Kanter, M.D., University of Alabama at Birmingham. The promising results of this study, which show patients have an almost complete elimination of VOCs and ACS, suggest LentiGlobin for SCD has real potential to provide a significant impact for people living with sickle cell disease.

LentiGlobin for SCD was designed to add functional copies of a modified form of the -globin gene (A-T87Q-globin gene) into a patients own hematopoietic (blood) stem cells (HSCs). Once patients have the A-T87Q-globin gene, their red blood cells can produce anti-sickling hemoglobin, HbAT87Q, that decreases the proportion of HbS, with the goal of reducing sickled red blood cells, hemolysis and other complications.

As of March 3, 2020, a total of 37 patients have been treated with LentiGlobin for SCD to-date in the HGB-205 (n=3) and HGB-206 (n=34) clinical studies. The HGB-206 total includes: Group A (n=7), B (n=2) and C (n=25).

HGB-206: Group C Updated Efficacy Results

In Group C of HGB-206, 25 patients were treated with LentiGlobin for SCD and have up to 24.8 months of follow-up (median of 12.1; min.-max.: 2.824.8 months). Results from Group C are as of March 3, 2020 and include efficacy data for 16 patients who had at least a Month 6 visit, and safety data for 18 patients, which includes two patients who were at least six months post-treatment but results from a Month 6 visit are not available.

In 16 patients with six or more months of follow-up, median levels of gene therapy-derived anti-sickling hemoglobin, HbAT87Q, were maintained with HbAT87Q contributing at least 40% of total hemoglobin. At last visit reported, total hemoglobin ranged from 9.6 16.2 g/dL and HbAT87Q levels ranged from 2.7 9.4 g/dL. At Month 6 the production of HbAT87Q was associated with a reduction in the proportion of HbS in total hemoglobin. Patients had a median of 60% HbS. All patients in Group C were able to stop regular blood transfusions and remain off transfusions at three months post-treatment.

There was a 99.5% mean reduction in annualized rate of VOC and ACS among the 14 patients who had at least six months of follow-up and a history of VOCs or ACS, defined as four or more VOC or ACS events in the two years prior to treatment. These 14 patients had a median of eight events in the two years prior to treatment (min.-max.: 4 28 events).

There were no reports of serious VOCs or ACS at up to 24 months post-treatment in patients with at least six months of follow-up (n=18). As previously reported, one non-serious Grade 2 VOC was observed in a patient approximately 3.5 months post-treatment with LentiGlobin for SCD.

In sickle cell disease, red blood cells become sickled and fragile, rupturing more easily than healthy red blood cells. The breakdown of red blood cells is hemolysis and this process occurs normally in the body. However, in sickle cell disease hemolysis happens too quickly due to the fragility of the red blood cells, which results in hemolytic anemia.

Patients treated with LentiGlobin for SCD demonstrated improvement in key markers of hemolysis, which are indicators of the health of red blood cells. Lab results assessing these indicators were available for the majority of the 18 patients with 6 months of follow-up. The medians for reticulocyte counts (n=15), lactate dehydrogenase (LDH) levels (n=13) and total bilirubin (n=16) improved compared to screening and stabilized by Month 6. In patients with Month 24 data (n=5) these values approached the upper limit of normal by Month 24. These results suggest treatment with LentiGlobin for SCD is improving biological markers of sickle cell disease.

Assays were developed by bluebird bio to enable the detection of HbAT87Q and HbS protein in individual red blood cells as well as to assess if HbAT87Q was pancellular, present throughout all of a patients red blood cells. Samples from a subset of patients in Group C were assessed. In nine patients who had at least six months of follow-up, the average proportion of red blood cells positive for HbAT87Q was greater than 70%, and on average more than 85% of red blood cells contained HbAT87Q at 18 months post-treatment, suggesting near-complete pancellularity of HbAT87Q distribution.

HGB-206: Group C Safety Results

As of March 3, 2020, the safety data from all patients in HGB-206 are generally reflective of underlying SCD and the known side effects of hematopoietic stem cell collection and myeloablative conditioning. There were no serious adverse events related to LentiGlobin for SCD, and the non-serious, related adverse events (AEs) were mild-to-moderate in intensity and self-limited.

One patient with a history of frequent pre-treatment VOE, pulmonary and systemic hypertension, venous thrombosis, obesity, sleep apnea and asthma had complete resolution of VOEs following treatment, but suffered sudden death 20 months after treatment with LentiGlobin for SCD. The patients autopsy revealed cardiac enlargement and fibrosis, and concluded the cause of death was cardiovascular, with contributions from SCD and asthma. The treating physician and an independent monitoring committee agreed this death was unlikely related to LentiGlobin for SCD gene therapy.

The presentation is now available on demand on the EHA25 website:

About HGB-206

HGB-206 is an ongoing, Phase 1/2 open-label study designed to evaluate the efficacy and safety of LentiGlobin gene therapy for SCD that includes three treatment cohorts: Groups A (n=7), B (n=2) and C (n=25). A refined manufacturing process that was designed to increase vector copy number (VCN) and improve engraftment potential of gene-modified stem cells was used for Group C. Group C patients also received LentiGlobin for SCD made from HSCs collected from peripheral blood after mobilization with plerixafor, rather than via bone marrow harvest, which was used in Groups A and B of HGB-206.

LentiGlobin for Sickle Cell Disease Regulatory Status

bluebird bio reached general agreement with the U.S. Food and Drug Administration (FDA) that the clinical data package required to support a Biologics Licensing Application (BLA) submission for LentiGlobin for SCD will be based on data from a portion of patients in the HGB-206 study Group C that have already been treated. The planned submission will be based on an analysis using complete resolution of severe vaso-occlusive events (VOEs) as the primary endpoint with at least 18 months of follow-up post-treatment with LentiGlobin for SCD. Globin response will be used as a key secondary endpoint.

bluebird bio anticipates additional guidance from the FDA regarding the commercial manufacturing process, including suspension lentiviral vector. bluebird bio announced in a May 11, 2020 press release it plans to seek an accelerated approval and expects to submit the U.S. BLA for SCD in the second half of 2021.

About LentiGlobin for Sickle Cell Disease

LentiGlobin for sickle cell disease is an investigational gene therapy being studied as a potential treatment for SCD. bluebird bios clinical development program for LentiGlobin for SCD includes the ongoing Phase 1/2 HGB-206 study and the ongoing Phase 3 HGB-210 study.

LentiGlobin for SCD received orphan medicinal product designation from the European Commission for the treatment of SCD.

The U.S. FDA granted orphan drug designation, regenerative medicine advanced therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for SCD.

LentiGlobin for SCD is investigational and has not been approved in any geography.

bluebird bio is conducting a long-term safety and efficacy follow-up study (LTF-303) for people who have participated in bluebird bio-sponsored clinical studies of betibeglogene autotemcel for -thalassemia or LentiGlobin for SCD. For more information visit: https://www.bluebirdbio.com/our-science/clinical-trials or clinicaltrials.gov and use identifier NCT02633943 for LTF-303.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders, including cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using three gene therapy technologies: gene addition; cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash., Durham, N.C., and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

LentiGlobin and bluebird bio are trademarks of bluebird bio, Inc.

bluebird bio Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the companys development and regulatory plans for the LentiGlobin for SCD product candidate, and the companys intentions regarding the timing for providing further updates on the development of the product candidate. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the COVID-19 pandemic and resulting impact on our operations and healthcare systems will affect the execution of our development plans or the conduct of our clinical studies; the risk that even if LentiGlobin for SCD addresses ACS and VOC events, that it may not address progressive organ damage experienced by patients with SCD; the risk that the efficacy and safety results observed in the patients treated in our prior and ongoing clinical trials of LentiGlobin for SCD may not persist or be durable; the risk that the efficacy and safety results from our prior and ongoing clinical trials will not continue or be repeated in when treating additional patients in our ongoing or planned clinical trials; the risk that the HGB-206 and HGB-210 clinical studies as currently contemplated may be insufficient to support regulatory submissions or marketing approval in the United States and European Union; the risk that regulatory authorities will require additional information regarding our product candidate, resulting in a delay to our anticipated timelines for regulatory submissions, including our application for marketing approval. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Visit link:
New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird...

As the COVID-19 pandemic unfolds around the world, the call for cutting-edge research is louder than ever. Human health has become a top priority for scientists, policymakers, and the public, inspiring investment in vaccines and other novel solutions to the most complicated biomedical questions.

For 35 years, The Pew Charitable Trusts has supported risk-taking among early career biomedical scientists. This year, 37 researchers join the Pew Scholars Program in the Biomedical Sciences,the Pew Latin American Fellows Program in the Biomedical Sciences, andthe Pew-Stewart Scholars Program for Cancer Research, receiving multiyear grants to pursue scientific interests in the United States and Latin America.

The 2020 scholars and fellows are embarking on groundbreaking research projects (visit our research pagesfor more) designed to advance human health at a time when the world needs scientific ingenuity the most

Disease, caused by viral and bacterial infections and environmental triggers, poses a serious threat to public health. The immune system is the human bodys best line of defense against illness, and researchers in this years class will investigate how various immune factors work together to help thwart disease.

The influenza virusknown as the flucan lead to other health complications, including secondary bacterial pneumonia. To uncover why this occurs, one researcher will assess how the flu alters the function of immune and lung cells to increase susceptibility to pneumonia.

HIV can also hide quietly inside humans and infect their immune cells, where the virus can remain dormant for a long period. However, the virus is known to emerge once a persons immunity weakens. One researcher will explore how this occurswork that may help to treat HIV and AIDS.

To better grasp the trajectory of diseases, researchers will also examine how environmental factorssuch as diet, sleep, and stressinfluence an animals ability to manage inflammatory chemicals during infection. By looking at how inflammation can trigger future infections and increase vulnerability to other diseases such as cancer and diabetes, researchers hope to uncover new treatment approaches.

Several researchers in the 2020 class will investigate human development and aging through the lens of gene activation, cellular function, and immunity.

Female mammals are born with a stockpile of oocytes, or egg cells, with mechanisms that protect them from protein deterioration and metabolic imbalances before fertilization. One researcher will evaluate this process, aiming to help slow or prevent the fertility clock from expiring.

Maternal antibodies found in a mothers milk play an important role in early childhood development, helping infants to metabolize nutrients and protecting them from infection. These antibodies also foster beneficial gut bacteria, and one researcher will identify microbial species in the gut that help to regulate growthwork that could help address infant malnutrition.

Finally, scientists have observed that females typically live longer than males. To understand why, one researcher will assess whether sex-based differences in immunity affect the way we age. Researchers will also examine how cells remove toxic proteins, compartmentalize nutrients, and maintain the health of the mitochondria as we agework that may inform how to extend healthy life spans and enhance the way we live.

Cancer, characterized by the uncontrolled growth of abnormal cells in the body, is a complex disease that takes on many forms. Several researchers will explore how to better detect, prevent, and defend against this devastating disease.

To improve cancer detection methods, one researcher will examine unique sequences from cell-free DNAwhich is shed by tumorsto help identify abnormal gene patterns associated with certain stages or types of cancers. This work could help devise a cheaper and more sensitive blood test to detect cancer.

Breast cancer affects about 2.1 million women globally each year. By investigating how normal cellular processes go awryfor example, how certain protein building blocks or RNA molecules are incorrectly modified during the development of breast cancerresearchers hope to identify new targets for small molecule drugs that could halt cancers growth and spread.

Cancers have also found unique ways to survive and thrive in the human body. For example, leukemia stem cells evade detection by cloaking themselves with proteins that render them invisible to the immune system. This years cancer researchers will investigate the many ways in which cancer resists therapy and is able to recur.

The brain is made up of more than 100 billion nerves that control all bodily functions and interpret signals from the outside world. Several researchers in this years class will inspect its structure and explore how it drives complex behaviors.

To analyze how different regions of the brain cooperate to make decisions, researchers will study how animals filter information from their surroundings and generate an appropriate behavioral response. For instance, one researcher will examine how an infants brain senses hunger and directs the child to cry out for food.

To better grasp how the brain develops, researchers will use single-cell technologies to construct a family tree of the human cerebral cortexthe brains outer layerand then determine whether any branches of this cerebral family tree are missing or altered in people with autism or schizophrenia.

Finally, after identifying the neural circuits in the brain that regulate sugar cravings, researchers will assess whether artificially activating these sugar-sensing circuits can elevate mood, or if suppressing them triggers depression and anxietywork that could develop new mental health therapies.

Kara Coleman directs The Pew Charitable Trusts biomedical programs, including the biomedical scholars, Pew-Stewart Scholars for Cancer Research, and Latin American fellows programs,and Jennifer Villa is a principal associate supporting the programs.

Read more from the original source:
37 Scientists Embarking on Innovative Biomedical Research - The Pew Charitable Trusts

COVID-19 impact will also be included and considered for forecast.

Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Thalassemia Treatment Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Sample

Global Thalassemia Treatment Market 2018-2024Brandessence Market Research is working on a new report titleGlobal Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Global Thalassemia Treatment Market Reports

Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (4) called Hemoglobin H.

Beta Thalassemia causesadditionalformation of alpha globins, which develops alpha globin tetramers (a4) that store in the erythroblast (immature red blood cell).Thalassemia is caused by mutations in the DNA of cells that make hemoglobin.

Factors that increase risk of Thalassemia include Family history of thalassemia and certain ancestry.Possible complications of Thalassemia includeIron overload, Infections, Bone deformities, splenomegaly, slowed growth rate of child and Heart problems.

Thalassemia signs and symptoms include Fatigue, Weakness, Pale or yellowish skin, Facial bone deformities, slow growth, abdominal swelling, Dark urine, chest pain,cold hands and feet, poor feeding, greater susceptibility to infections. Diagnosis of Thalassemia includesa complete blood count (CBC), a reticulocyte count,Iron count, Genetic testing and prenatal testing. Treatment of Thalassemia depends on the type and severity of Thalassemia such as Blood transfusions, Bone marrow or stem cell transplant, Surgery and Gene therapy.

Global Thalassemia Treatment Market has been segmented on the basis ofType of Treatment, Diagnosis, End usersand Geography. On the basis of Type of TreatmentGlobal Thalassemia Treatment Market is classified into Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy and Others.On the basis of DiagnosisGlobal Thalassemia Treatment Market is classified into Perinatal Testing, Prenatal Testing, Pre-Implantation and Other.On the basis of the End user the Global Thalassemia Treatment Market is classified into Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries and others.

The regions covered in Global Thalassemia Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Global Thalassemia Treatment Market Dynamics

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.22.2. Average 18.5%14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin deficiency.Occurrence of Thalassemia is reported to increase steadily over the years across different regions. This can be due to population migration, intermarriages, genetic as well as environmental factors prompting the condition and its implications.Systematic Drugs under Pipeline, Rising Scope for Gene Therapy and increasing awareness towards Thalassemia are some opportunities in the forecast period for theGlobal Thalassemia Treatment Market.

Global Thalassemia Treatment MarketRegional Analysis

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

The alpha thalassemia testing market has aemergent trend in the countries with traditional groups like Mediterranean countries, African countries and few countries in Asia Pacific. Furthermore, in Asia Pacific region the growth in similar community marriage practices and high fertility ratewith alpha thalassemia patients have been detected. This is expected to raiseacceptance of blood transfusion and chelation therapy treatments during the forecast period.A latestimprovement in the testing of alpha Thalassemia may determine the risk of the disease by in vitro examination of the embryo. While there are various such tests available in theGlobal Thalassemia Treatment Market but lack of awareness leads to the neglect and delayed diagnosis of the diseased state.

Most frequently prone area for alpha thalassemia is Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait practically affects 6% to 35% of the population in these ethnic groups. Middle East & Africa is likely to be the fastest risingGlobal Thalassemia Treatment Market during the forecast period.

Key Benefits for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Thalassemia Treatment Market report helps to identify opportunities in market place.Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.Global Thalassemia Treatment Market Segmentation

Global Thalassemia Treatment Market: By Type of Treatment Analysis

Blood TransfusionChelating TherapyBone Marrow TransplantStem Cell TransplantSurgeryGene TherapyOtherGlobal Thalassemia Treatment Market: By Diagnosis Analysis

Perinatal TestingPrenatal TestingPre-ImplantationOtherGlobal Thalassemia Treatment Market: By End user Analysis

HospitalsBiotechnological LaboratoriesDiagnostic LaboratoriesEducational Research InstitutesPharmaceutical IndustriesOtherGlobal Thalassemia Treatment Market: By Regional & Country Analysis

North AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Thalassemia Treatment Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Thalassemia Treatment Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Thalassemia Treatment Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Thalassemia Treatment Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Thalassemia Treatment Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Thalassemia Treatment Market.

Market Forecast: Here, the report offers a complete forecast of the Global Thalassemia Treatment Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Continued here:
2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 - Cole of Duty

The Induced Pluripotent report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2026. The data included in this Induced Pluripotent report provides detailed information of the geographic landscape, competitive scenarios and upcoming opportunities in the Industry. The inclusion of the statistical records in the Induced Pluripotent report helps in authenticating the results that are being presented and thus provide a clear vision and indication to clients in understanding the response of the participants.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-market

Few of the major competitors currently working in the induced pluripotent market areBristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Segmentation: Global Induced Pluripotent Market

By Product Category

By Cell Type

By Application

By End-User

By Geography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-market

Key Developments in the Market:

Market Restraints

Table of Contents

1. Introduction2. Market Segmentation3. Market Overview4. Executive Summary5. Premium Insights6. Global, By Component7. Product Type8. Delivery9. Industry Type10. Geography

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-induced-pluripotent-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:Corporatesales@databridgemarketresearch.com

More here:
Global Induced Pluripotent Market Revenue Opportunities and Analysis with Key Players Thermo Fisher Scientific; Cell Applications, Inc.; Axol...

A Wayne, PA-based startup called NFlection has raised $20 million in their Series A launch round. F-Prime and venBio Partners provided the cash for the rare disease biotech, funding their first clinical trial for NFX-179 Gel in adult patients with cutaneous neurofibromatosis type-1, or NF-1. This study allows us to determine the drugs ability to suppress key biomarkers involved in the progression of neurofibromas and will aid in the selection of doses for a larger Phase2bstudy, saidCEO Christopher Powala.

Having steered an idiopathic pulmonary fibrosis drug to a big-money deal with Gilead, Galapagos has enlisted e-therapeutics and its silico phenotypic screening platform to discover some new approaches to modulating a specific mechanism involved in IPF and possibly other fibrotic diseases. The Oxford biotech will be responsible for the computational activities while Belgium-based Galapagos performs the experimental testing.

BryoLogyx has forged a pair of agreements with Neurotrope. The company agreed to acquire Neurotropes preclinical data and drug product for use of bryostatin-1 in an immuno-oncology application and to supply synthetic bryostatin-1 for use in clinical trials and potential commercialization for the treatment of Alzheimers disease and other neurodegenerative diseases. Neurotrope has been developing bryostatin-1 under a cooperative research and development agreement with the National Cancer Institute. They didnt disclose financial terms.

California-based drug developer Rezolute has bagged the FDAs pediatric disease designation for RZ358, its mid-stage drug for congenital hyperinsulinism. The disease, characterized by excess insulin secretion, causes repeated episodes of low blood sugar. The condition often goes unnoticed in infants, putting them at risk of complications of recurring hypoglycemic events, including developmental delays, seizures, coma and death.

Read this article:
Rare disease startup NFlection scores $20M in Series A haul; Gilead partner Galapagos signs pact with Oxford biotech - Endpoints News

Karyopharm Doses First Patient in Brain Cancer Trial

Karyopharm Therapeutics (KPTI) announced that it has dosed the first patient for its Phase 1/2 clinical trial. The study aims to assess the potential of oral Selinexor in combination with standard of care therapy in treating patients suffering from newly diagnosed or recurrent glioblastoma. This multi-site study is expected to enroll nearly 400 patients in clinical sites spread across the United States, Europe and Israel.

The randomized Phase 1/2 study is scheduled to be conducted in two phases. The Phase 1 study is mainly aimed at determining dosage, while the Phase 2 randomized efficacy exploration trial aims to independently assess three different combination regimens in three treatment arms in patients with newly diagnosed GBM (Arms A and B) or with recurrent GBM (Arm C). Arms A and B will examine Selinexor in conjunction with radiation therapy with or without temozolomide. Arm C aims to assess the potential of Selinexor and lomustine.

The primary endpoint of the Phase 1 study is to determine the maximum tolerated dose and the recommended dose to be given in the second phase trial. Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm, said, While selinexor has been most extensively studied in patients with hematologic malignancies, there is increasing evidence that selinexor may also play an important role in the treatment of a variety of solid tumors, including patients with GBM. Phase 2 study will have the primary endpoints of progression-free survival in patients with newly diagnosed GBM and overall survival (OS) in patients with recurrent GBM.

Selinexor is an oral selective inhibitor of the nuclear export (SINE) compound. The compound is known to block the cellular protein XP01, which plays an important role in controlling various tumor suppressor proteins as well as other relevant oncoproteins. In its previous studies, the drug candidate has shown the ability to cross the blood-brain barrier. In a Phase 2 KING study, aimed to assess Selinexor as a single agent in patients with recurrent GBM, it showed robust anti-cancer activity.

Selinexor is already approved by the FDA as a treatment for patients with relapsed or refractory multiple myeloma. It is currently the only FDA-approved XP01 inhibitor and has two additional supplemental New Drug Applications under review by the FDA. The first application seeks label extension for the drug candidate to include its use in treating patients with multiple myeloma after at least one prior line of therapy. The second application pertains to the treatment of patients suffering from relapsed or refractory diffuse large B-cell lymphoma. The drug candidate is in the market under the brand name XPOVIO.

Karyopharm mainly focuses on developing therapies for treating different cancers and other major diseases.

Dynavax (DVAX) announced that it has completed the process of enrolment for its Heplisav-B Phase 1 clinical trial. The company expects the final immunogenicity data to be available by Q4. Dynavax has enrolled 119 patients for the study, which aims to evaluate the drug candidate in adult patients suffering from end-stage renal disease who are starting or already undergoing hemodialysis.

HBV-24 is an open-label, single-arm study which is designed to evaluate a new 4-dose regimen of HEPLISAV-B. The patients enrolled in the study have not previously been treated with a hepatitis B vaccine. Robert Janssen, MD, Chief Medical Officer at Dynavax. We are evaluating a 4-dose regimen of HEPLISAV-B in this study, which we believe may provide an important hepatitis B vaccination alternative for adults with end-stage renal disease on dialysis. We look forward to a scientific presentation of the final data at an appropriate forum in the future. Hepatitis B is a viral disease of the liver and may lead to other complications such as liver cancer and cirrhosis.

The trial aims to assess the drug candidates immunogenicity at study week 20 and safety over the 68-week study duration. Safety and effectiveness of HEPLISAV-B have yet to be established in adults on hemodialysis. The hepatitis B virus is highly infectious, and there is no cure for this. However, the disease may be prevented by effective vaccination. Adults may contract the infection through various means, including infected blood transfusion.

HEPLISAV-B combines hepatitis B surface antigen with Dynavaxs proprietary Toll-like Receptor (TLR) 9 agonist CpG 1018. The drug candidate works by boosting the immune response in a patient. It is indicated for preventing infection caused by all known subtypes of hepatitis virus. HEPLISAV-B is currently only prescribed to adults 18 years or older.

BeyondSpring (BYSI) reported positive data from its PROTECTIVE-2 Phase 2 superiority trial. The study aims to test the potential of Plinabulin, the companys lead drug candidate, in treating breast cancer.

PROTECTIVE-2 assessed the superiority potential of the drug candidate in preventing chemotherapy-induced neutropenia in breast cancer patients treated with docetaxel, doxorubicin and cyclophosphamide. The patients were administered 20mg/m2 of Plinabulin combined with 6mg of Neulasta. The control group was given 6mg of Neulasta alone. The data showed that the combination improved compliance with targeted chemotherapy. It enabled more patients to take the optimal chemotherapy dose and regimen.

None of the patients in combination group downgraded chemotherapy from the TAC regimen to the TC regimen, whereas 18.2 percent patients in the control cohort had to downgrade. Dr. Ramon Mohanlal, BeyondSprings Chief Medical Officer and EVP, R&D, said, This approach provides potential benefits for both clinicians and patients: clinicians may gain greater control over cancer care, and patients may experience better clinical outcomes and an improved quality of life. The improvement in the prevention of Grade 4 neutropenia that is seen with the Plinabulin-Neulasta combination is even more important in todays healthcare environment due to the devastating impact of COVID-19 on immune-suppressed patients. The company plans to release interim top line data from the Phase 3 trial in the near future.

Plinabulin is a differentiated immune and stem cell modulator. The drug candidate is currently in late-stage clinical development phase for treating cancer and to alleviate chemotherapy-induced neutropenia. The drug mainly acts as an antigen presenting cell inducer and aids T-cell activation. In combination, of Plinabulin and G-CSF play complementary roles in reducing CIN. PROTECTIVE-2 is a superiority study and pits the combination against Neulasta. Apart from Plinabulin, BeyondSpring has three immune-oncology product candidates in its development pipeline. It also has a drug discovery platform which uses the ubiquitination degradation pathway.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Original post:
Karyopharm Brain Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha